Bibliographic Details
| Title: |
Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer. |
| Authors: |
Jazieh, Khalid, Babiker, Hani M., Foster, Nathan R., Fruth, Briant, Carr, Ryan Michael, Alberts, Steven R, Conboy, Caitlin, Tran, Nguyen H., Hartgers, Mindy L., Halfdanarson, Thorvardur Ragnar, Starr, Jason S., Sonbol, Mohamad Bassam, Jones, Jeremy Clifton, Ahn, Daniel H., Kankeu Fonkoua, Lionel Aurelien, Wu, Christina, Pedersen, Katrina Sophia, Bekaii-Saab, Tanios S., McWilliams, Robert R. |
| Source: |
Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p727-727, 121p |
| Database: |
Supplemental Index |
